Integra LifeSciences Holdings Corporation EBITDA 2011-2026 | IART

Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.^[1]

EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.

EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.

However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.

Annual EBITDA Integra LifeSciences Holdings Corporation

2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
70.8 M	152 M	279 M	237 M	193 M	186 M	132 M	65.2 M	129 M	89.5 M	77.9 M	55.8 M	92.3 M	71.3 M

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
279 M	55.8 M	131 M

Quarterly EBITDA Integra LifeSciences Holdings Corporation

2025-Q2	2025-Q1	2024-Q3	2024-Q2	2024-Q1	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-509 M	-11.8 M	-4.39 M	678 K	14.1 M	29.8 M	15.5 M	39.5 M	-	68.2 M	63.2 M	50.1 M	-	60.6 M	56.1 M	35.2 M	-	65.9 M	22.2 M	56.3 M	-	-15.5 M	99.9 M	59.4 M	-	107 M	81.6 M	52.7 M	-	72.9 M	58.3 M	29.7 M	-	84.4 M	58.6 M	40.4 M	-	50.6 M	48.7 M	33 M	-	51.1 M	41.6 M	22.7 M	-	4.55 M	29.6 M	9.2 M	-	58.9 M	43.8 M	30 M	-	55.6 M	32.5 M	30.8 M

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
107 M	-509 M	30.1 M

References

Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.

EBITDA of other stocks in the Medical devices industry

Issuer	EBITDA	Price	% 24h	Market Cap	Country
Apollo Endosurgery APEN	-30.2 M	-	-	$ 475 M	USA
GenMark Diagnostics, Inc. GNMK	-3.98 M	-	-	$ 1.77 B	USA
Aziyo Biologics AZYO	-24.1 M	-	1.37 %	$ 20.5 M	USA
AdaptHealth Corp. AHCO	473 M	$ 13.38	2.29 %	$ 1.81 B	USA
Allied Healthcare Products AHPI	-815 K	-	3.58 %	$ 2.21 M	USA
Avinger AVGR	-16.3 M	-	-20.74 %	$ 369 K	USA
BIOLASE BIOL	-15.1 M	-	-13.19 %	$ 166 K	USA
Axonics Modulation Technologies AXNX	-53.2 M	-	-	$ 3.31 B	USA
BioSig Technologies BSGM	-67.6 M	-	37.08 %	$ 85.7 M	USA
Obalon Therapeutics, Inc. OBLN	-9.8 M	-	-5.86 %	$ 30.6 M	USA
EDAP TMS S.A. EDAP	-18 M	$ 3.28	1.86 %	$ 123 M	France
Conformis CFMS	-42.2 M	-	-	$ 16.4 M	USA
Cardiovascular Systems CSII	-32.1 M	-	0.15 %	$ 844 M	USA
Cytosorbents Corporation CTSO	-13.5 M	$ 0.6	-1.96 %	$ 37.3 M	USA
ClearPoint Neuro CLPT	-23.4 M	$ 11.08	-1.16 %	$ 314 M	USA
Dynatronics Corporation DYNT	-1.97 M	-	14.99 %	$ 929 K	USA
Eargo EAR	-106 M	-	-	$ 10.2 M	USA
Electromed ELMD	10.7 M	$ 25.74	-1.0 %	$ 218 M	USA
CryoLife, Inc. CRY	23.2 M	-	-4.14 %	$ 702 M	USA
Second Sight Medical Products EYES	-27.1 M	-	-0.97 %	$ 54.4 M	USA
GBS GBS	-9.67 M	-	-0.57 %	$ 7.12 M	USA
Globus Medical GMED	757 M	$ 90.74	-3.16 %	$ 12.3 B	USA
Soliton, Inc. SOLY	-14.1 M	-	-1.42 %	$ 435 M	USA
Hancock Jaffe Laboratories, Inc. HJLI	88.4 K	-	-1.98 %	$ 98.3 M	USA
Itamar Medical Ltd. ITMR	-8.53 M	-	0.03 %	$ 1.58 B	Israel
Misonix, Inc. MSON	-15.9 M	-	-	$ 462 M	USA
Neovasc NVCN	-31.1 M	-	-	$ 111 M	Canada
Helius Medical Technologies HSDT	-12.4 M	$ 2.08	-1.89 %	$ 1.26 M	USA
Butterfly Network BFLY	-65.5 M	$ 5.16	-5.84 %	$ 1.09 B	USA
Intersect ENT, Inc. XENT	-64.8 M	-	-	$ 955 M	USA
OrthoPediatrics Corp. KIDS	-18.1 M	$ 15.14	-4.3 %	$ 355 M	USA
Delcath Systems DCTH	898 K	$ 10.55	-2.68 %	$ 378 M	USA
IRIDEX Corporation IRIX	-2.05 M	$ 1.04	-3.7 %	$ 17.6 M	USA
CONMED Corporation CNMD	120 M	$ 36.79	-2.85 %	$ 1.14 B	USA
LivaNova PLC LIVN	228 M	$ 61.29	-3.34 %	$ 3.34 B	Britain
Inspire Medical Systems INSP	64.9 M	$ 55.11	0.07 %	$ 1.62 B	USA
LENSAR LNSR	-21 M	$ 5.35	2.69 %	$ 64 M	USA
Integer Holdings Corporation ITGR	352 M	$ 84.64	-0.83 %	$ 2.94 B	USA
Pulmonx Corporation LUNG	-52.6 M	$ 1.23	-4.3 %	$ 50 M	USA
Invacare Corporation IVC	-65 M	-	-	$ 24.7 M	USA
Edwards Lifesciences Corporation EW	1.42 B	$ 82.28	-1.41 %	$ 48.1 B	USA
MiMedx Group MDXG	78.8 M	$ 3.4	1.8 %	$ 502 M	USA
Nevro Corp. NVRO	-118 M	-	-	$ 217 M	USA
NanoVibronix NAOV	-22 M	-	-	$ 1.08 M	USA
Myomo MYO	-13.5 M	$ 0.82	-1.19 %	$ 34.3 M	USA
Cutera CUTR	-148 M	-	-10.19 %	$ 1.99 M	USA
Natus Medical Incorporated NTUS	51.9 M	-	1.94 %	$ 1.05 B	USA
Orthofix Medical OFIX	-4.11 M	$ 11.91	-3.33 %	$ 472 M	Curacao